Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Safety and Effectiveness in Treatment Naive CLL Patients with or without High Risk Features Treated with Veno Under Real-World Conditions in Austria, Germany, and Switzerland

Ingo Schwaner, Holger F. Hebart, Christoph Losem, Thomas Wolff, Caroline Lehmann, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi

Blood (2023) 142 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2023-174387

Published: 2023

Journal Articles

Multilayer Profiling of MRD in Patients with Relapsed/Refractory CLL Treated with Venetoclax-Based Regimens in a Real-World Setting

Katia Pini, Alessio Bruscaggin, Maria Cristina Pirosa, Gabriela Forestieri, Joyce Marques de Almeida, Georg Stüssi, Mathias Oertli, Xenia Schmidt, Johannes Huelsenbeck, Thomas Noesslinger, Ingo Schwaner, Monica Gallucci, Heidi Simmons, Davide Rossi, Adalgisa Condoluci

Blood (2023) 142 (Supplement 1): 3257.

https://doi.org/10.1182/blood-2023-180509

Published: 2023

Journal Articles

Real-World Effectiveness and Safety of Venetoclax in Combination with Obinutuzumab in Treatment-Naive CLL Patients - Data from the Observational Study Verve

Ingo Schwaner, Holger Hebart, Christoph Losem, Thomas Wolff, Kirsten Famulla, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi, Thomas Noesslinger

Blood (2022) 140 (Supplement 1): 12412–12413.

https://doi.org/10.1182/blood-2022-162273

Published: 2022

Journal Articles

Safety and Effectiveness of Venetoclax/Rituximab in Bcri-Naïve and Bcri-Exposed Patients with Relapsed/Refractory CLL Under Real-Life Conditions - Data from the Observational Verve Study

Davide Rossi, Holger Hebart, Christoph Losem, Thomas Wolff, Xenia Schmidt, Kirsten Famulla, Burkhard Schmidt, Thomas Noesslinger, Ingo Schwaner

Blood (2021) 138 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2021-145555

Published: 2021